Quotes about muscular dystrophy: 10 Quotes to Help You When You’re Feeling Down

10 Quotes to Help You When You’re Feeling Down

We know dealing with muscular dystrophy sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention.

To help you on your journey, we’ve gathered a few quotes we thought might help pick you up during those moments when everything feels a bit bleak.

MORE: Watch what happens when children meet a man with muscular dystrophy

1. “Always remember you are braver than you believe, stronger than you seem, smarter than you think and twice as beautiful as you’ve ever imagined.” – Dr. Seuss

2. “Never believe that a few caring people can’t change the world. For, indeed, that’s all who ever have.” – Margaret Mead

3. “A hundred years from now, it will not matter what kind of car I drove, what kind of house I lived in, how much money I had in the bank…but the world may be a better place because I made a difference in the life of a child.

– Forest Witcraft

4. “Live so that when your children think of fairness, caring, and integrity, they think of you.” – H. Jackson Brown, Jr.

5. “Too often we underestimate the power of a touch, a smile, a kind word, a listening ear, an honest compliment, or the smallest act of caring, all of which have the potential to turn a life around.” – Leo Buscaglia

6. “Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.”

– Thomas Edison

7. “Act as if what you do makes a difference. It does.“ – William James

8. “You’ve survived 100 percent of everything in your life so far, so there’s a pretty good chance that you’ll survive whatever is next.” – Timber Hawkeye

9. “How wonderful it is that nobody need wait a single moment before starting to improve the world.” – Anne Frank

10. “Courage doesn’t always roar. Sometimes courage is the quiet voice at the end of the day saying, ‘I will try again tomorrow.’”

– Mary Anne Radmacher

MORE: Seven people with chronic illnesses who used a body-shaming experience to raise awareness

Muscular Dystrophy News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Famous Quotes & Sayings About Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Famous Quotes & Sayings

List of top 12 famous quotes and sayings about duchenne muscular dystrophy to read and share with friends on your Facebook, Twitter, blogs.

Top 12 Quotes About Duchenne Muscular Dystrophy

#1. If you don’t know exactly where you are going (and why),that is exactly where you will end up. – Author: Christopher Babson
#2. Only one endowed with restless vitality is susceptible to pessimism. You become a pessimist – a demonic, elemental, bestial pessimist – only when life has been defeated many times in its fight against depression. –
Author: Emil Cioran
#3. I don’t get recognized all the time, but it tends to happen more in America, and people are so lovely when they do. – Author: Michelle Dockery
#4. One discards rhyme, not because one is incapable of rhyming neat, fleet, sweet, meet, treat, eat, feet but because there are certain emotions or energies which are nor represented by the over-familiar devices or patterns.
Author: Ezra Pound
#5. You’ll see a lot of funny stuff, you’ll see a lot of daddy-knows-best stuff, you’ll see a lot of me and my wife trying to hold the family together. – Author: Russell Simmons
#6. Old is the tree and the fruit good,
Very old and thick the wood.
Woodman, is your courage stout?
Beware! the root is wrapped about
Your mother’s heart, your father’s bones;
And like the mandrake comes with groans. – Author: Robert Louis Stevenson
#7. It was nearly impossible to keep anything a secret, especially from her
sisters, the youngest of whom – Hyacinth – could probably have won the war against Napoleon in half
the time if His Majesty had only thought to draft her into the espionage service.Author: Julia Quinn
#8. Look, sir, I know Angua. She’s not the useless type. She doesn’t stand there and scream helplessly. She makes other people do that. – Author: Terry Pratchett
#9. Making friends with the impersonal necessity of death is an ethical way of installing oneself in life as a transient, slightly wounded visitor. – Author: Rosi Braidotti
#10. LORD GORING: (after a long pause) Nobody is incapable of doing a foolish thing. Nobody is incapable of doing a wrong thing. –
Author: Oscar Wilde
#11. Again I was lying. That’s when he looked down – Author: Steve Osborne
#12. I did say I don’t feel as worthy as so many of the recipients … He said he’d seen some of my work, which is amazing, and was a fan of Gavin and Stacey. – Author: Sheridan Smith

10 Quotes to Help Muscular Dystrophy Patients When They’re Down

When living with muscular dystrophy, there are some days that feel much harder than others. No matter the person, everyone needs a little help to get through the day. Whether the person is the patient, doctor, caregiver, or loved one, muscular dystrophy is difficult to manage. The most important thing to remember is that taking care of one’s mind is just as important as caring for the body.

If the day is getting to be too much, take a step back. Evaluate the situation and turn your mind towards positive thoughts. If you can put off any activity, do it. Not everything needs to be taken care of that instant.

If you need a bit of a pick-me-up, look to these quotes for guidance.

It is not an easy task living with muscular dystrophy. Sometimes, there will be days that feel really hard to handle. It does not matter who the individual is; everyone needs help now and again to get through difficult days. Irrespective of who the person is, whether it be the patient, their caregiver, doctor, or a loved one, those dealing with muscular dystrophy may find it difficult to manage alone. One of the most important things to remember is to take care of one’s mind the same way one would be take care of the body. If the day becomes too much, it is best to take a step back. In such cases, it is important to evaluate the situation and also to think positive thoughts. If you are able to postpone the day’s work, it’s a good idea to do so; not everything needs to be taken care of at that particular moment. When you feel low and depressed, try taking a look at the following quotes to provide some quick help and guidance:

  1. “Always remember that you are braver than you believe, stronger than you seem, smarter than you think, and twice as beautiful as you have ever imagined.
    ” – Dr. Seuss. With this in mind, one should redirect all negative thoughts outwards based on the day; it’s not right to bottle up emotions.
  2. “Never believe that a few caring people cannot change the world. For, indeed, that is all who ever have.” – Margaret Mead.
  3. “A hundred years from now, it will not matter what kind of car I drove, what kind of house I lived in, how much of the money I had in the bank, but the world may be a much better place because I had made a difference in the life of a child.” – Forest Witcraft.
  4. “Live so when your children think of fairness, integrity, and caring, they can think of you.” – H. Jackson Brown Jr.
  5. “Too often, we underestimate the power of a touch, a smile, kind word, listening ear, honest compliment, or even the smallest act of caring since all of which can have the potential to turn the life around.” – Leo Buscaglia.
  6. “Our greatest weakness lies in the act of giving up. One of the most certain ways to success is to always try just one more time. ” – Thomas Edison.
  7. “You have survived 100 percent of everything in your life so far, so there is a pretty good chance that you would survive whatever is next as well.” – Timber Hawkeye.
  8. “Act as if what you do makes a difference. It does.” – William James.
  9. “How wonderful it is that nobody would need to wait a single moment before starting off to improve the world.” – Anne Frank.
  10. “Courage does not always roar. Sometimes, courage is the quiet voice at the end of the day saying, ‘I will try again tomorrow.’” – Mary Anne Radmacher.

Top 12 Quotes & Sayings About Muscular Dystrophy

We have common enemies today. It’s called childhood poverty. It’s called cancer. It’s called AIDS. It’s called Parkinson’s. It’s called Muscular Dystrophy. — Jerry Doyle

People need to remember that to balance the federal budget off the backs of the poorest people in the country is simply unacceptable. You don’t pull feeding tubes from people. You don’t pull the wheelchair out from under the child with muscular dystrophy. — Mike Huckabee

If it came to a magic genie, I would ask him for two extra wishes. One would be that no one would have to live with the muscular dystrophy disease or any disease. And the second one would be world peace, that we just stop fighting, talk about things, and we could live in harmony once again, like God intended us to do. — Mattie Stepanek

My disease is a very rare form of muscular dystrophy, called disautonomic mitochondrial myopathy.Mattie Stepanek

I knew you’d know,” Mom said in a stabilizing, more confident, yet still husky voice. A smile broke across her face in the simple relief of her only remaining child not being shocked by the death of her youngest. She smiled genuinely, perhaps for the first time since cradling Dustin’s body as the fire truck alarm blared towards the house in response to her 911 call. Her son had died that morning in her arms as she tried resuscitating him with her own breath, but the first indication of her daughter’s reaction was calm. The child raised to expect death met the first moments of the news with seeming serenity. — Darcy Leech

Muscular dystrophy … was never seen until Duchenne described it in the 1850s. By 1860, after his original description, many hundreds of cases had been recognised and described, so much so that Charcot said: ‘How is it that a disease so common, so widespread, and so recognisable at a glance – a disease which has doubtless always existed – how is it that it is recognised only now? Why did we need M. Duchenne to open our eyes?’ — Oliver Sacks

There’s already a lot of active research going on using the Crispr technology to fix diseases like Duchenne muscular dystrophy or cystic fibrosis or Huntington’s disease. They’re all diseases that have known genetic causes, and we now have the technology that can repair those mutations to provide, we hope, patients with a normal life. — Jennifer Doudna

A lot of times I say to myself, “I wished I could be worthy of all the compliments that people give me sometimes.” I’m not inventing anything that’s going to stop cancer or muscular dystrophy or anything, but I like to feel that my time and talent is always there for the people that need it. When someone do say something negative, most times I think about it, but it don’t bother me that much.B.B. King

Her words felt like a new beginning, a turning of a page, and, ominously, rang like the beginning of a final chapter. — Darcy Leech

My cousin was diagnosed with muscular dystrophy, and it’s just a really tragic disease, and as of yet there is no cure, so I feel I want to get it as much publicity to do it as I can. — Nick Robinson

Every year, once a year, in Maryland, I go for a week and overnight camp with about 50 to 60 kids with muscular dystrophy, all ages, seven to 21. And it is really fun. I have some great friends there and wonderful counselors. — Mattie Stepanek

Willpower doesn’t change everything. We can’t be just anything we want to be. My mother couldn’t will herself to be like she was when she was thirty or forty. She couldn’t choose to be normal – her muscles were degenerating. — Darcy Leech

Patient Identified Disease Burden in Facioscapulohumeral Muscular Dystrophy

Muscle Nerve. Author manuscript; available in PMC 2014 Jul 15.

Published in final edited form as:

PMCID: PMC4097080


, MD,1, MS,2, AS,1, MD,1 and , MD, MS-CI1

Nicholas E Johnson

1Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642

Christine Quinn

2Center for Community Health, University of Rochester, 46 Prince St #1001, Rochester, NY, 14607

Eileen Eastwood

1Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642

Rabi Tawil

1Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642

Chad R Heatwole

1Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642

1Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642

2Center for Community Health, University of Rochester, 46 Prince St #1001, Rochester, NY, 14607

The publisher’s final edited version of this article is available at Muscle NerveSee other articles in PMC that cite the published article.
Supplementary Materials

Supplemental Table 1.

GUID: 841A4699-76E8-4869-A25F-78A5E278A2FB

Supplemental Table 2.

GUID: F231773F-1F91-44C4-BF84-FFAE5C210784



The multitude of symptoms associated with facioscapulohumeral muscular dystrophy (FSHD) disease burden are of varying importance. The extent of these symptoms and their cumulative effect on the FSHD population is unknown.


We conducted interviews with adult FSHD patients to identify which symptoms have the greatest effect on their lives. Each interview was recorded, transcribed, coded, and analyzed using a qualitative framework technique, triangulation, and 3-investigator consensus approach.


1375 quotes were obtained through 20 patient interviews. 251 symptoms of importance were identified representing 14 themes of FSHD disease burden. Symptoms associated with mobility impairment, activity limitation, and social role limitation were most frequently mentioned by participants.


There are multiple themes and symptoms, some previously under-recognized, that play a key role in FSHD disease burden.

Keywords: Facioscapulohumeral muscular dystrophy, quality of life, disease burden, neuromuscular disorders, symptoms


Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder characterized by bifacial, scapulohumeral, truncal, and lower extremity weakness with relative sparing of the deltoid and forearm muscles.1,2 FSHD is the third most common muscular dystrophy with an estimated prevalence between 1:15,000 and 1:20,000.3,4 In addition to muscular weakness, individuals with FSHD may have pain associated with impaired joint stabilization or nerve stretch, hearing loss,5 retinal vascular abnormalities (Coat syndrome),6–8 and atrial arrhythmias.9,10

Here we report findings from a series of open-ended FSHD interviews which identify and quantify the most critical issues and symptoms to FSHD patients.

Materials and Methods

We selected subjects over the age of 21 with either genetically confirmed FSHD or symptoms consistent with the diagnosis of FSHD with an affected and genetically confirmed first degree family member. A purposive sampling strategy was utilized to capture a wide range of age and disability.

We conducted in-depth interviews with subjects by telephone. Participants were asked to identify which symptoms of FSHD have the greatest impact on their quality of life (QOL) and describe how their lives are affected by having the disease. All interviews were audio-recorded and transcribed verbatim for later analysis.

Following transcription, 3 investigators independently analyzed the interviews using a framework technique for qualitative analysis.11,12 Each interview quote was familiarized, indexed, charted, mapped, matched and interpreted by a team consensus approach.11,12 Similar quotes across participants were recorded, and the quote frequency for each symptom was determined. Like symptoms were classified into symptomatic themes of FSHD health, and each theme was further categorized as a physical, mental, social, or disease-specific aspect of FSHD health. Lastly, a model and frequency table was created based on cumulative participant data to highlight the most critical areas of patient-identified FSHD health.

The entire study was conducted with informed consent and institutional review board approval.


Twenty individuals participated in this study. The age of onset, deletion size, education level and occupational status was available for 13 members of our sample (supplemental table 1).

From the 20 FSHD participants, 1375 direct quotes were coded identifying 251 symptoms of importance. These symptoms represented 14 symptomatic themes and 4 major domains (). The most frequently identified symptoms were “impaired walking” followed by “difficulty with stairs”, “reliance on family members”, “difficulty lifting objects”, “limitations physically on what one can do”, and “difficulty getting places without handicap accessibility”(supplemental table 2). “Difficulty with mobility and ambulation” and “FSHD-specific activity impairment” were the symptomatic themes that had the highest number of representative quotes (). A full list of participant-identified symptoms, quote frequency, and theme classification is provided (supplemental table 2).

A. Conceptual Model of Quality of Life in FSHD patients as represented by domains, subdomains and themes. Quote frequencies are provided in parentheses. B. Quote frequencies subdivided by subdomain.


This study uses extensive patient interviews to identify the symptoms of highest importance to a sample of FSHD patients. In many instances, these identified symptoms are underreported in the FSHD literature and represent potential areas of therapeutic intervention.

Participants identified poor mobility as a theme that has a major impact on their lives. Advances in orthotic devices as well as improved accessibility to buildings may play a substantial role in further relieving future FSHD disease burden.

The effect FSHD has on a patient’s social role and emotional status is often overlooked in the clinical setting, yet these issues have a paramount importance to patients as highlighted through our interviews. Indeed, the frequency that patients mentioned the importance of social role limitations was greater than the frequency of quotes involving the cardinal features of FSHD (fascioscapulohumeral weakness). This is in agreement with other studies that have highlighted the need to address social and emotional factors in muscle diseases and those that have noted a relationship between emotional distress and the perception of disease severity.13–15 The emotional and social burdens of FSHD patients should not be neglected, as these aspects may be treatable through social services, social networking programs, education, anti-depressants, psychotherapy, and counseling.

The results from our study supplements prior work evaluating QOL in FSHD.13–24 Previous studies have largely used generic instruments (such as the SF-36 and the CIS-fatigue subscale) to characterize the impact of FSHD on patient QOL. 13–24 Unfortunately, generic instruments may not be suitable for some neuromuscular diseases, as they can exclude questions that are highly relevant to a neuromuscular population while including questions that have limited relevance.14 While prior studies primarily utilize generic QOL measures to identify a global reduction in overall QOL, increased pain, and worsening fatigue in FSHD, our study further qualifies and quantifies these findings using patients’ own words and perspectives.

Previous work has also created and tested generic neuromuscular instruments by combining patient input from diverse neuromuscular populations.25,26 The Individualized Neuromuscular QOL measure was initially created using combined interview data from no fewer than 8 distinct neuromuscular populations.25 In our study all interview data came exclusively from FSHD patients. Not surprisingly, there is both overlap and uniqueness when comparing data between studies. For instance, our sample of FSHD patients did not identify “locking” or myotonia as an issue of importance, whereas a combined neuromuscular population including myotonic patients did.25 In addition, compared to myotonic dystrophy type-1 (DM1), FSHD participants report greater difficulty with proximal arm weakness, truncal weakness, facial weakness, and impaired body image.27 Our FSHD participants also identified 113 unique issues not reported by DM1 patients through similar interviews.27 These findings highlight some of the differences between neuromuscular populations and the potential need for disease-specific QOL outcome measures.28–31

This qualitative study was limited by its sample size. Future studies will need to validate the issues identified here using a larger and more diverse FSHD patient sample. All interviews were conducted by telephone. Due to this constraint, strength and functional testing were not performed. Future research will need to determine the association between patient reported disease burden and functional measures as well as age, gender, duration of symptoms, and genetics.

In conclusion, FSHD participants identify a wide array of symptoms that impact their QOL. These symptoms help to define the disease from the patient’s perspective and are potentially amendable to future therapeutic intervention.


The project described was supported by the Muscular Dystrophy Association and by Grant #1K23AR055947 from NIAMS/NIH. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the supporting agencies.


FSHDFacioscapulohumeral muscular dystrophy
QOLQuality of life
DM1myotonic dystrophy type-1


1. Padberg G. Thesis. Leiden, the Netherlands: University of Leiden; 1982. Fascioscapulohumeral disease. [Google Scholar]2. Tyler FH, Stephens FE. Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family. Ann Intern Med. 1950;32:640–660. [PubMed] [Google Scholar]3. Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord. 2001;11:525–529. [PubMed] [Google Scholar]4. Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet. 2009;75:550–555. [PubMed] [Google Scholar]5. Trevisan CP, Pastorello E, Ermani M, Angelini C, Tomelleri G, Tonin P, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol. 2008;13:1–6. [PubMed] [Google Scholar]6. Bass SJ, Sherman J, Giovinazzo V. Bilateral Coats’ response in a female patient leads to diagnosis of facioscapulohumeral muscular dystrophy. Optometry. 2011;82:72–76. [PubMed] [Google Scholar]7. Bindoff LA, Mjellem N, Sommerfelt K, Krossnes BK, Roberts F, Krohn J, et al. Severe fascioscapulohumeral muscular dystrophy presenting with Coats’ disease and mental retardation. Neuromuscul Disord. 2006;16:559–563. [PubMed] [Google Scholar]8. Shields CL, Zahler J, Falk N, Furuta M, Eagle RC, Jr, Espinosa LE, et al. Neovascular glaucoma from advanced Coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol. 2007;125:840–842. [PubMed] [Google Scholar]9. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol. 2011;24:423–428. [PubMed] [Google Scholar]10. Laforet P, de Toma C, Eymard B, Becane HM, Jeanpierre M, Fardeau M, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998;51:1454–1456. [PubMed] [Google Scholar]11. McColl E. Developing questionnaires. In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials. Oxford: Oxford Press; 2005. pp. 9–25. [Google Scholar]12. Ritchie J, Spencer L. Anonymous Analyzing Qualitative Data. Routledge: 1994. Qualitative data analysis for applied research; pp. 173–194. [Google Scholar]13. Graham CD, Rose MR, Grunfeld EA, Kyle SD, Weinman J. A systematic review of quality of life in adults with muscle disease. J Neurol. 2011;258:1581–1592. [PubMed] [Google Scholar]14. Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle & Nerve. 2012 in press. [PubMed] [Google Scholar]15. Rose MR, Sadjadi R, Weinman J, Akhatar T, Pandya S, Kissel JT, et al. The role of disease severity, illness perceptions and mood on quality of life in muscle disease. Muscle & Nerve. 2012 in press. [PubMed] [Google Scholar]16. Abresch RT, Carter GT, Jensen MP, Kilmer DD. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Care. 2002;19:39–48. [PubMed] [Google Scholar]17. Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BG, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005;76:1406–1409. [PMC free article] [PubMed] [Google Scholar]18. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571–579. [PubMed] [Google Scholar]19. Kalkman JS, Zwarts MJ, Schillings ML, van Engelen BG, Bleijenberg G. Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue. Neurol Sci. 2008;29(Suppl 2):S238–S240. [PubMed] [Google Scholar]20. Minis MA, Kalkman JS, Akkermans RP, Engels JA, Huijbregts PA, Bleijenberg G, et al. Employment status of patients with neuromuscular diseases in relation to personal factors, fatigue and health status: a secondary analysis. J Rehabil Med. 2010;42:60–65. [PubMed] [Google Scholar]21. Padua L, Aprile I, Frusciante R, Iannaccone E, Rossi M, Renna R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve. 2009;40:200–205. [PubMed] [Google Scholar]22. Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schroder R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:1473–1481. [PubMed] [Google Scholar]23. Jensen MP, Hoffman AJ, Stoelb BL, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med Rehabil. 2008;89:320–328. [PMC free article] [PubMed] [Google Scholar]24. Miro J, Raichle KA, Carter GT, O’Brien SA, Abresch RT, McDonald CM, et al. Impact of biopsychosocial factors on chronic pain in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Hosp Palliat Care. 2009;26:308–319. [PMC free article] [PubMed] [Google Scholar]25. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL) Neurology. 2007;68:1051–1057. [PubMed] [Google Scholar]26. Sansone VA, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose MR, et al. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol. 2010;17:1178–1187. [PubMed] [Google Scholar]27. Heatwole CR, Bode R, Johnson NE, Quinn C, Martens WB, McDermott MP, et al. Patient Reported Impact of Symptoms in Myotonic Dystrophy Type-1: (PRISM-1) Neurology. 2012 in press. [PMC free article] [PubMed] [Google Scholar]28. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217–S232. [PubMed] [Google Scholar]29. Wiklund I, Dimenas E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials. 1990;11:169–179. [PubMed] [Google Scholar]30. Birbeck GL, Kim S, Hays RD, Vickrey BG. Quality of life measures in epilepsy: how well can they detect change over time? Neurology. 2000;54:1822–1827. [PubMed] [Google Scholar]31. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care. II: Design, analysis, and interpretation. BMJ. 1992;305:1145–1148. [PMC free article] [PubMed] [Google Scholar]

Finding treatments for Duchenne muscular dystrophy

Ilan Ganot never planned a career in drug development. But everything changed for him and his wife, Annie, when their son, Eytani, was diagnosed two years ago with a rare disease.

“Even just looking at Wikipedia, you see wheelchair by 10, 11, 12, and that most of the boys don’t make it past their early 20s,” Annie said in an interview. “It was devastating. Words can’t describe, as a parent, how you feel.”

Eytani, 4, has Duchenne muscular dystrophy, a genetic muscle-wasting disease. There’s no cure for DMD, and no drugs are approved for it in the U.S.

Ilan, who was working with hedge funds at JPMorgan when Eytani was diagnosed in October 2012, decided to change that. After quitting his job, moving the family to the Boston areaa hub for biotechnology researchand raising $17 million, he founded Solid Ventures. It’s a for-profit company focused solely on Duchenne. It aims to step in where traditional drug companies sometimes won’t go.

Read MoreWhy dying kids can’t get the drugs they need

“In rare diseasesand there are thousands of themwe find it difficult sometimes to substantiate the economic value, to justify for big companies to roll up their sleeves and jump right in,” Ganot said. “What we’re left with is a lot of patients that are left without drugs, and a lot of science that is not getting developed.”

Eytani Ganot, a 4-year-old with Duchenne muscular dystrophy, has inspired his father, Ilan, to leave his hedge fund job and form a for-profit company working for a cure for the muscle-wasting disease.

Source: The Ganot Family

Solidso named for the English translation of Eytani’s name from Hebrewaims to take promising science out of labs or off pharmaceutical companies’ shelves and advance it through development. The company has now made its first moves, delving into three initiatives to treat DMD in different ways.

Read MoreWhy there’s no end in sight for higher drug costs

The first draws a pharmaceutical giant into the fray. Solid is collaborating with Pfizer to test one of its clinical assets, with plans to decide whether to move into human testing by early next year. Ganot declined to name the therapeutic area in which Pfizer had been focusing the drug, but said it may be possible to move directly to the mid-stages of clinical testing because enough is understood about the molecule.

Solid’s second approach could be more transformative for DMDif it’s successful. The company has formed a subsidiary focused on gene therapy called Solid GT, which “if it works changes the disease completely,” Ganot said. “It’s relevant for every patient.”

Gene therapy involves inserting a gene into patients’ cells, usually using a virus as a delivery method. Progress in the technology has been halting but has started to accelerate in recent years, with companies including Bluebird Bio and Sangamo showing some early success.

The Ganots at their home in Newton, Mass.

Source: The Ganot Family

Solid GT is guided by a scientific advisory board chaired by the University of Pennsylvania’s James Wilson, Ganot said. Its goal is to take a smaller form of the gene dystrophinthe key to DMD, and also the largest known human geneand administer it to patients so it can help them make a smaller version of the protein important for muscle function, also called dystrophin.

Ganot said the company expects to be in human trials with the gene therapy approach within two years.

Read MoreRx for drugstore sticker shock? Not Obamacare

The third initiative, called Solid Suit, focuses on preserving muscle function, “repurposing military technologies for the benefit of health care and patients with disabilities,” Ganot said.

“DMD is a muscle-wasting disease, and when the muscle works, it gets wasted, basically, and doesn’t regenerate like it does in healthy people,” Ganot explained. “We believe that if we could preserve much of that muscle, when disease-modifying interventions like exon-skipping or gene therapy are introduced, the more muscle we have left, the better chances of an efficacious treatment.”

Exon-skipping is a technology being pursued by Sarepta Therapeutics and Prosensa, both aiming to file for approval of their drugs by the end of this year. Their medicines focus on treating specific mutations that drive DMD, and they’re both starting with the one that affects the most patientsnot the one that Eytani has.

Solid’s multiple approaches to one disease are part of its strategy to diversify its efforts to lower investment risk, Ganot said. They’re also structured in ways that provide the most flexibility to the programs. Solid GT is a subsidiary, which “gives us better options in the future on partnering, raising specific money for a particular program, on discontinuing or funding some more,” Ganot said.

“All three would help all patients,” he said. As for his own son, Ganot said he’s confident Solid will make a difference.

“We’re aggressive, we raised enough money to do what we need to do, we have the right people, and very soon we’ll have the right treatments, too.”

—By CNBC’s Meg Tirrell

Muscular dystrophy

Muscular dystrophy (MD) refers to a group of genetic, hereditary muscle diseases that cause progressive muscle weakness. Muscular dystrophies are characterised by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue. This leads to muscle wasting, and probable death in early adulthood – the age of mortality depends on the type of MD.


Causes of MD

Animal models of MD

Gene therapy

Stem cell therapy

Non-animal methods

Clinical trials of gene therapies




Nine diseases are always classed as MD: Duchenne, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss. However, there are more than 100 diseases with similarities to MD. Most types of MD are multi-system disorders that manifest in various organs such as the heart, gastrointestinal and nervous systems, endocrine glands, skin, and eyes, amongst others.

Some forms of MD, including the most common, are sex-linked and so predominantly affect boys; others are autosomal dominant meaning that only one copy of the gene variant needs to be passed on from a parent, or autosomal recessive where both parents must pass on a mutant copy of the gene.

Two boys are born every week in the UK with the commonest form, Duchenne muscular dystrophy (DMD), which first appears at ages 2–16 and causes death in early adulthood. Although all forms of MD are still incurable, recent research has opened many promising avenues of treatment.

Causes of MD

DMD is caused by errors in the largest known gene in the human genome, dystrophin. Without dystrophin, muscle cells weaken with continuous contraction and eventually die. There is no cure yet, but researchers are optimistic that animal work will lead to gene therapy and stem cell therapy which could have a major impact on patients’ quality of life.
Miyoshi myopathy and limb-girdle MD arise when the protein dysferlin, responsible for repairing muscle damage, is mutated.

Some forms of MD are caused by mutations that disrupt an assembly of muscle proteins called the dystrophin-glycoprotein complex.

Animal models of MD

Various other mouse models are throwing light on how damage is caused in MD.

A strain of mice and some breeds of dogs suffer ‘naturally’ from muscular dystrophy. Together with GM mice, these animals are being used to understand more about the disease and its treatmentANCHOR.

The mdx mouse is a naturally occurring strain with a mutation similar to that in DMD. There is also a naturally occurring mutation in golden retrieversANCHOR that exactly matches the human DMD mutation in the dystrophin gene. These models make a major contribution to research into the physiopathology of DMD, ie how the disease disrupts normal body functions; and are invaluable to scientists for testing a variety of potential therapies.

The membranes surrounding muscle cells are frequently damaged, and this causes an influx of calcium to the injured site, where it forms vesicles that plug the damage. Dysferlin is a protein responsible for repairing muscle damage, and mice lacking the gene that makes it developed a progressive form of muscle dystrophy. At a microscopic level, muscle membranes that were damaged were unable to repair themselvesANCHOR.

Some forms of MD are caused by mutations that disrupt an assembly of muscle proteins called the dystrophin-glycoprotein complex. When one of these proteins, dystroglycan, was removed from the muscles of MD mice, the disease was far milder than in controls because so-called satellite cells stepped in and repaired some of the damageANCHOR. Some forms of MD are caused by mutations in enzymes called glycosyltransferases, which lead to defects in the addition of sugars to dystroglycan. By restoring levels of a sugar-transferring enzyme called LARGE, or by over-expressing the gene that makes it, the disease was prevented in MD mice.

Subtle defects in the processing of a single protein that protects muscle cells from damage can lead to rare but devastating forms of MD, found in humans and mice. In muscle-eye-brain disease and Fukuyama congenital MD, defects in enzymes that process the structural protein dystroglycan affect muscles and cause additional developmental brain abnormalities including mental retardation. Two studies in mice demonstrated that dystroglycan is defective, and this will help doctors to provide accurate diagnosis and genetic counselling to patients and their familiesANCHOR ANCHOR.

In several kinds of congenital MD half the patients lack a protein called merosin, or laminin m; a laminin-deficient MD mouse model has been useful for investigating gene therapyANCHOR.

Mice lacking the sarcoglycan gene mimic limb-girdle muscular dystrophy in humans; in contrast to some other MD animal models, they show ongoing muscle necrosis with age, a hallmark of the human diseaseANCHOR.

Gene therapy

Gene therapy aims to deliver the normal dystrophin gene to the affected muscle in DMD, producing dystrophin in sufficient quantities to halt the wasting processANCHOR. This is difficult because the ‘unedited’ dystrophin gene is huge. Effective delivery systems to get genes into muscles have been successful in miceANCHOR.

A successful approachANCHOR has been to use the gene for a related protein, utrophin, which is smaller. When it was given to affected mice, their muscles produced utrophin and reduced muscle damage. A smaller dystrophin ‘minigene’ has also been engineered. It even reversed progression of the disease in miceANCHOR.

Muscle development is restrained in normal animals by a protein called myostatin, and blocking this protein causes muscles to over-develop. This has been seen for 200 years in Belgian Blue cattle. The myostatin gene in mice was sequenced in 1997. When the gene for myostatin was knocked out in mdx mice using an antibody, their body weight and muscle mass increased and they showed less muscle degeneration. This has the potential to slow Duchenne and Becker muscular dystrophyANCHOR.

Another way of sidestepping the size of the dystrophin gene has been to use a small ‘antisense’ RNA molecule injected into the muscle to ‘patch up’ the mutation. This molecule binds to specific sequences in the dystrophin RNA and interfers with a process called splicing, resulting in near-normal dystrophin production and relieving many of the symptoms. A single injection gave near-normal dystrophin production for over three months – a long time to a mouseANCHOR. Obviously, it is vitally important not only to test for dystrophin protein production, but also to find out if it has a long-term effect on the symptoms. Human clinical trials are now underway (see Clinical trials of gene therapies).

Targeted gene repair has been successful in golden retrievers that suffer naturally from DMD. This approach used a manufactured molecule containing both DNA and RNA, which enabled the cell to use its own repair mechanism to correct the gene defectANCHOR.

Gene therapy has also been successful in restoring normal muscle function in mice with laminin-deficient MD. Scientists replaced the missing gene with a ‘minigene’ containing elements of the agrin gene, as agrin has a similar effect to laminin on nerves and muscles. Offspring with the agrin gene showed weight gain, growth patterns and movement ability similar to that of normal mice. Another route to congenital MD treatment may lie in drugs that raise agrin concentrationsANCHOR.

Stem cell therapy

Muscle stem cells taken from newborn mice and grown in tissue culture, then injected into mdx mice (a DMD model) appeared to develop into muscle, nerve and blood vessel cells. An added marker gene proved that the new cells came from the injected stem cells, and the new cells made dystrophinANCHOR. Human synovial stem cells, taken from the membrane lining the knee joint, have also repaired damaged muscle in MD mice and have been shown to make dystrophinANCHOR.

Using MD mice lacking the sarcoglycan gene (equivalent to limb-girdle muscular dystrophy in humans), scientists have used mesangioblasts, stem cells taken from blood vessels, and found they transdifferentiated into muscle fibresANCHOR. The scientists went on to try this with the golden retriever DMD model, and also had promising results: the dogs with the crippling genetic disorder were able to walk and even jump againANCHOR. If mesangioblasts can be collected from human MD patients, they may offer a new avenue for treating the disease. The approach would involve collecting mesangioblasts from a patient’s blood, genetically ‘correcting’ the cells in the laboratory, allowing them to multiply, and injecting them back into the patient’s bloodstream. The cells would then migrate to the patient’s muscles, and begin producing healthy muscle cells. Because the cells would be from the patient’s own body, their immune system wouldn’t reject them.

Muscle has also been regenerated in MD mice by injecting bone marrow (‘hematopoietic’) stem cells, which normally gives rise to blood cellsANCHOR.

Another potential therapeutic approach is the use of muscle growth factors. Researchers using MD mice have discovered that stem cells travel long distances to reach an injury and that they are summoned by a substance called mIGF-1ANCHOR.

Non-animal methods

Antisense RNA ‘patches’ are now being tested in human muscle cells, reducing reliance on animal research. Muscle cells isolated from biopsies taken when the condition is diagnosed are grown in culture to assess the effectiveness of newly developed patches.

However, although cell culture experiments can help to assess the potential of novel approaches to treatment, only by understanding and testing such therapies in the complex environment of the whole body can we develop clinically useful treatments. To develop clinical trials into effective treatments, the DMD community will continue to rely heavily on the mdx mouse.

Clinical trials of gene therapies

Targeting all skeletal muscles is complicated, but experimental clinical studies are in progress in three areasANCHOR.

Two early stage gene-therapy clinical trials using adeno-associated viral (AAV) vectors have recently started; one in limb-girdle muscular dystrophy and one in DMD. They will assess the safety of the intramuscular administration (ie injected into the muscle) of the AAV vectors, and how well it works.

Two more early stage studies are also underway in DMD, testing antisense RNA patches (See Gene therapy, above). These are administered by injection into a small muscle on the top of the foot. Human studies have shown that this small foot muscle is relatively well preserved compared to other muscles in boys up to the age of around 15.

A fifth study is evaluating a drug that allows the dystrophin gene sequence of DMD patients to be ‘read’, even though they have nonsense mutations that would normally prevent this.

These studies should provide ‘proof-of-principle’ of these experimental approaches in humans, but it is likely that further work will be needed to refine the procedures before they can be used to treat MD.


Talking about one retriever, Dr Giulio Cossu of the San Raffaele Scientific Institute, said: “One of the most emotional moments I had was when I saw the severely impaired dog running again. I couldn’t have anticipated it going so well. I hope that this result can be transferred to humans.”

Professor Dominic Wells of Imperial College, London, points out: “Although cell culture experiments can help us to assess the potential of novel approaches to treatment, only by understanding and testing such therapies in the complex environment – the whole organism – can we develop clinically useful protocols. As clinical trials develop into effective treatments, the DMD community will have a lot to thank the mdx mouse for.”

  1. Allamand V, Campbell K (2000) Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Gen 9, 2459
  2. Sharp N, Kornegayb J, Van Camp S et al (1992) An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13, 115. DOI 10.1016/0888-7543(92)90210-J
  3. Bansal D, Miyake K, Vogel SS et al (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423, 168
  4. Cohn RD, Henry MD, Michele DE (2002) Disruption of Dag1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110, 639
  5. Muntoni M, Brockington M, Brown SC (2004) Glycosylation eases muscular dystrophy. Nature Medicine 10, 76
  6. Michele DE, Barresi R, Kanagawa M (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418, 417
  7. Moore SA, Saito F, Chen J (2002) Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418, 422
  8. Duclos F, Straub V, Moore SA et al (1998) Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 142(6):1461
  9. Cox GA, Cole NM, Matsumura K, Phelps SR et al (1993) Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364, 725
  10. Fisher KJ, Jooss K, Alston J et al (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nature Medicine 3, 306
  11. Tinsley JM, Potter AC, Phelps SR et al (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349
  12. Wang B, Li J, Xiao X (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Nat Acad Sci 97, 13714
  13. Wagner KR, McPherron AC, Wini NK, Lee S-J (2002) Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52, 832
  14. Lu QL, Mann CJ, Lou F et al (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Medicine 9, 1009
  15. Bartlett RJ, Stockinger S, Denis MM et al (2000) In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nature Biotechnology 18, 615
  16. Moll J, Barzaghi P, Lin S et al (2000) An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413, 302
  17. Qu-Petersen Z, Deasy B, Ron Jankowski R et al (2002) Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157, 201
  18. De Bari CD, Dell’Accio F, Vandenabeele FF et al (2003) Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J Cell Biol 160, 909
  19. Sampaolesi M, Torrente Y, Innocenzi A et al (2003) Cell therapy of α-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301, 487
  20. Sampaolesi M, Blot S, D’Antona G et al (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444 574
  21. Corbel SY, Lee A, Yi L et al (2003) Contribution of hematopoietic stem cells to skeletal muscle. Nature Medicine 9, 1528
  22. Musarò M, Giacinti C, Borsellino G et al (2004) Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Nat Acad Sci 101, 1206
  23. Muntoni F, Wells D (2007) Genetic treatments in muscular dystrophies. Curr Opin Neurol 20(5), 590

  • Animal(s): Dog, Mouse
  • Countries: United Kingdom
  • Research field(s): Anatomy and development, Bones and muscles, Genetics

Last edited: 5 November 2014 11:02

90,000 50 travel quotes: inspiration and motivation

In words we describe feelings, emotions and memories. Some people master them so skillfully that they make them experience an illusion and believe in things that seemed impossible.

Travel changes us, helps us grow and develop. Travel is the best education in the modern world!

I have collected for you quotes about the travels of the most famous poets, writers and philosophers. Their experience and the words that have appeared as a result will help to understand many everyday problems and even decide on an important step.

  1. “To speak a foreign language is to conquer its world and culture” – Franz Fanon.
  2. “Nothing develops the mind like travel” – Emile Zola.
  3. “Those who study need to travel” – Mark Twain.
  4. “Look at the world. He’s more amazing than dreams. ”- Ray Bradburry.
  5. “Investing in travel is investing in yourself” – Matthew Carsten.
  6. “Life is either a desperate adventure or nothing.” – Hellen Keller.
  7. “The road is best measured not in miles, but in friends.” – Tim Cahill.
  8. “Travel leaves you speechless, and then turns you into a better storyteller” – Ibn Battuta.
  9. “How I love feeling faceless in a city I’ve never been before” – Bill Bryson.
  10. “Never be afraid to go away from seas, borders, countries and thoughts” – Amin Maaluf.
  11. “There is something magical about it: you leave as one person and return completely different” – Kate Douglas Wiggen.
  12. “To travel is to develop” – Pierre Bernando.
  13. “As soon as you catch a traveler’s fever, you cannot be cured of it and you will be infected with it for the rest of your life.” – Michael Palin.
  14. “Oh, all those places you will visit!” – Dr. Seuss
  15. “The real traveler has no definite plan or intention to come anywhere” – Lao Tzu.
  16. “I haven’t been everywhere, but this is on my list” – Susan Sontag.
  17. “The traveler sees what he sees; tourists see what they have come to see ”- G.K.Chesterton.
  18. “The goal is not a place, but the ability to see the world differently” – Henry Miller.
  19. “Stop thinking about holes in the road, enjoy the adventure” – Fitjugh Mullan.
  20. “Take Only Memories, Leave Only Traces” – Chief Seattle
  21. “Once a Year, Visit a Place You Have Never Been” – The Dalai Lama.
  22. “Traveling is not something you are good at. This is what you do. ”- Gail Foreman.
  23. “To travel is to live” – Hans Christian Andersen
  24. “To travel is to realize that everyone is wrong about other countries” – Aldous Huxley
  25. “The world is a book, and those who do not travel have time to read only the first page “- Art.Augustine.
  26. “Do you want to travel far and fast? Travel light. Get rid of envy, intolerance, selfishness and fears ”- Cesar Pavese.
  27. “I have met a lot of people in Europe. I even got to know myself. ”- James Baldwin.
  28. “Not All Wanderers Have Lost Their Way” – JR Tolkien.
  29. “Traveling helps us to be humble. Each of us is just a tiny grain of sand in this desert of people ”- Gustave Flaubert.
  30. “People are able to find and know themselves only in adventure” – André Hyde.
  31. “We are not traveling in order to escape from life, but so that life does not escape from us” – Anonymous.
  32. “Tourists don’t know where they’ve already been, and travelers don’t know where they’ll go. ” – Paul Theroux.
  33. “It is not people who create travel, it is travel who creates people” – John Steinbeck.
  34. “Prejudice, intolerance and narrow-mindedness are detrimental to travel” – Mark Twain.
  35. “Travel is the only thing in the world, buying which, you become richer” – Anonymous.
  36. “If you do not honor other people’s traditions, religion and avoid people, it is better to stay at home” – James Michener.
  37. “I changed when I saw the moon shining from the other side” – Mary Ann Redmacher.
  38. “If you don’t know where you are going, any road will do.” – Lewis Carroll.
  39. “It’s hard to realize how wonderful the journey is until you put your head on the old, familiar pillow.” – Ling Yutan.
  40. “A traveler without the ability to observe is comparable to a bird without wings” – Mosley Eddin Saatan.
  41. “Only he who wanders opens new paths” – Norwegian proverb.
  42. “We travel the world to find beauty; we must keep it in ourselves, otherwise it will not open to us “- Ralph Waldo Emerson
  43. ” The further I go, the closer I get to myself “- Andrew McCarthy.
  44. “Every dreamer knows that it is absolutely real to miss a place where you have never been even more than where you have been.” – Judith Thurman.
  45. “Live, travel, do not regret anything and thank fate” – Jack Kerouac.
  46. “It’s not important where you end up, but what adventures will meet you along the way” – Penelope Riley.
  47. “He who lives sees a lot. The one who travels sees more. ”- Arabic proverb.
  48. “If you think an adventure is dangerous, try a routine. It is deadly ”- Paolo Coelho.
  49. “Travel Teaches Tolerance” – Benjamin Disraeli
  50. “The Adventure Is Worth It” – Aristotle.

If you are inspired by these travel quotes, also read inspirational career quotes from top multinationals and 11 truths about how travel changes us.

90,000 Epilepsy quotes – QuotesBox.org Epilepsy quotes – QuotesBox.org Considering all my problems, mysterious knee pain is overkill, although I have to admit worse things can happen to a person. For example: cancer, multiple sclerosis, neuromuscular disorders, emphysema, Alzheimer’s disease and AIDS. Not to mention congenital diseases such as muscular dystrophy, cerebral palsy, hemophilia and epilepsy. Not to mention wars, epidemics and famine. But what is interesting is that even with all this in mind, it is not at all easier to endure knee pain. David Lodge All people, men and women, constantly strive to lose their lives – the dull, joyless, meaningless life of their individuals.Always striving to get rid of it, and there are a thousand different ways to do this. The fever of avid gamblers and fighters for national revival; monomania of misers and perverts, researchers, sectarians and ambitious; compensatory psychosis of alcoholics, bookers, dreamers and morphine addicts; hallucinations of opium smokers, moviegoers and churchgoers . .. Aldous Huxley

Viktor Chernomyrdin: quotes – Vedomosti

But as for, he will not live to see – but we will all survive.We will live. In what configuration? Must be in a good configuration. And there is no need to make some kind of tragedy out of this. (about the 2000 elections)

And whoever tries to interfere – we know about them by sight! True, you can’t call it a face there!

Where were you before? When it was necessary to think, and not to cut from the shoulder seven times . .. But now they caught themselves, ran. And they all turned out to be behind. In the deepest sense. And Chernomyrdin warned.

We also had real budgets, but we still failed miserably.

We will defend this to prevent this from happening.

In our life, it is not very easy to determine where you will find and where you will lose. At some stage you will lose, but tomorrow you will gain, and properly.

One must be born in charisma.

The most important result of Peter’s reforms was the creation of favorable conditions for Western business people.

At least put you on the priest, at least in a different position – all the same there is no sense!

Let’s get into a fight – we will fail the next and future years as well.Who needs it? Who’s itchy hands? For those who itch, scratch it elsewhere.

Forever in Russia there is not what is needed.

Actually, not much success. But the main thing: there is a government!

Here is Mikhail Mikhailovich – the new Minister of Finance. I ask you to love and even love very much. Mikhail Mikhailovich is ready for love. (about Zadornov)

For the first time in many years, there has been a decrease in the discharge of livestock.

It is unlikely that the position determines or gives me any weight.Well, where is even more needed for a person who has already gone through everything. Everyone knows a lot about this life. I know a lot. Maybe even superfluous.

Everyone says that they are dissatisfied with the results of privatization, and I am dissatisfied, and I do not speak.

All of his statements, here are his buzzing there … even a pensioner somewhere, they say, he called me. I did not hear. But if I am a pensioner, then who is he? Grandfather is ordinary then. (about Luzhkov)

All the questions that were raised, we will collect them all in one place.

This is all so straightforward and perpendicular that I hate it.

You think that it’s far easy for me. It’s far from easy for me!

You said there, but we hiccuped here, but I am okay with that too.

The whole theory of communism was invented by two Jews…. I had Marx and Engels.

There is a disaster in Yugoslavia. A disaster is always bad!

They say that our satellite hangs idle. We have a lot of things hanging around, but it should work!

Yes, such people, but in such a state as Russia, have no right to live badly!

Go ahead, make a mistake, and we will correct it, as the president said.

The deputies all expressed their opinion that I should go – to be elected, more precisely.

His reaction, it will always, we will see, will be this or not. If not, it means such a reaction. If there is, then no reaction. (about Primakov)

If I had named everything what I have, you would be crying here!

If you do it – so big!

If there is no promotion, I will be fired without my consent. Not fired, but kicked out. (on the negotiations in Yugoslavia)

If I am a Jew – why should I be ashamed! I really am not a Jew.

Natural monopolies are the backbone of the Russian economy, and we will cherish this ridge like the apple of our eye.

There is still time to save face. Then you have to save other parts of the body.

Sick, coughing again in different ways. But the president is the president. (about Yeltsin)

Why should we join somewhere? We don’t need to enter anywhere! Usually, if we start to enter somewhere, we will definitely step somewhere! You see, Ukraine puts this vector so perpendicularly that no one understands anything.(on Ukraine’s accession to NATO)

Here you are not here!

And again I know how you can. And often, and as needed.

And whoever provokes us today, whoever throws up some Iranians, Iraqs and many other things, there will be none. There won’t even be any inclinations. On the contrary, all work will be built in order to destroy what has been accumulated over many years.

And who to ask, I ask you? These are there, those here, and those still no one has ever . ..

There will be no changes to take your breath away.Otherwise, in order for someone to do something, it will be necessary to take or take away from the other.

And those who survive will laugh themselves later.

Unfortunately, some of our collective members look like dead souls.

As someone said, appetite comes in times of trouble.

Whatever public organization we create, it turns out the CPSU.

Clinton got fucked for his Monica for a whole year. We have such through one. We will applaud them again. But the Constitution is another matter.It is written: you can’t go to Monica – don’t go! And go – answer. If you don’t know how … And we will live! I mean the Constitution!

When my … our country is in such a state, I will do everything, I will say everything! When I know that it will help, I will not keep behind my back!

When it is difficult, we will always last … What we need. (on the “helping hand” to Ukraine)

Whom will be elected in the next elections, we will work with that. And who is there to our liking, who is there below the heart – that’s another conversation.

We grumble like blacks. (on the plans of the government in September 1998)

Who says that the government is sitting on a bag of money? We are men and we know what we are sitting on.

Whoever tells me what, I will do that.

Our course is correct.

The locomotive of economic growth is like an elephant in a famous place …

The IMF mission left, and everyone immediately panicked – why, for what? Who are you offended?

People have a lot of money in stockings or socks.I don’t know where – it depends on the quantity.

May come true. It will come true if we do nothing.

My life was spent in an atmosphere of oil and gas.

We will conduct foreign policy with foreign hands

We will destroy our nuclear weapons together with America.

We can always be able to.

We have completed all points: from A to B.

We are still trying to milk those who are already lying.

We remember when oil was bad.They just said – the oil was gone. Then they pressed on the eggs so that they too were gone.

We will still live in such a way that our children and grandchildren will envy us!

Today we are at such a stage of economic reforms that they are not very visible.

We wanted the best, but it turned out as always. (6.08.1993, at a press conference on the monetary reform of July – August 1993)

We want to go forward, but we are always hindered by something.

In any language I can speak with everyone, but I try not to use this tool.

Let’s get up on our feet – we’ll lie down on another

We must all lie down on this and get what we should have.

We must do what our people need, not what we are doing here.

You have to think what to understand.

We are lucky in our life that this, in fact, historical time fell to our lot. Rejoice!

We do not need to step on the same rake that we already had.

Nobody bothers us to overfulfill our laws

The people have lived – and will be!

They tried to bend us, but failed.

Our president – he, in my opinion, has not seen money in his eyes for five or ten years. He doesn’t even know how much money we have.

Our immediate task today is to determine where we are today together with you.

Do not belittle your role and importance. This does not mean that you need to swell here and, as they say, here wave, wave something.

Not only to resist, but we will defend it in order to prevent this from happening.

Some of the principles that used to be principled were actually not principled.

It is impossible to think and it is not even necessary to think that the time will come when it will be easier.

Not a single country, by the way, got up from its knees in a vague state. By pursuing a vague policy. I am in favor of a revolutionary approach here.

But if we talk about today’s meeting, then I would, of course, give a satisfactory assessment. I don’t know any other assessments at all.

But we will count, and then everyone will know. And we come first. And if someone is too smart, let him think for himself, and then we will check.And we will report wherever we go.

But we will do the pension reform. There is where to roam.

But I do not want everything here, swoop: today I embraced one, tomorrow with another, then again – and off we go. Yes, it’s not far from the panel …

Well, so much dirt, so much fiction, so many perversions of individual politicians! These are not politicians, they are … I don’t want to name them, otherwise they will burst into tears right now.

Well, what can we combine with him? He has a cap, and I don’t wear anything yet.(about Luzhkov)

Well, who can replace me? I’ll kill you right away … Sorry.

Accused of what? Corruption? Whom? Me? Who? USA? Why did they suddenly wake up there?

We will survive the difficulties. We are not like that in Russia, Russians, so as not to survive. And we know what and how to do.

The posts of deputy prime minister at a time like ours are like a post on which it is written: If you get in, you will kill!

Right or wrong is a philosophical question.

Government is not a body where, as many people think, it is possible only with language.

The government is such a complex organism, if you constantly change it, shuffle it – only the worst will be the result. I know that, it was my job.

The government is accused of monetarism. I admit – we are sinful, we are studying. But bad.

It is necessary to support the government, but we go hand in hand, hand over hand, everything go hand in hand. We also strive not only from hand to hand, but somewhere else. As Chekhov said.

There is no need to introduce Anatoly Borisovich. Everyone knows him, whoever does not know will find out.(about Chubais)

The President showed and will show more.

Forecasting is difficult, especially when it comes to the future.

We learned to pronounce words. Now I would like to learn how to count money.

Let it be natural selection, but quickly and carefully guided. (about the dismissals of members of the government)

A working president and a working government – so this song can turn out.

We laid the rails in six years, now it’s up to the locomotive.And so that the helmsman was … with his head. So that not the cars were moved to them, but he was dragging them.

Reforms in Russia are not a car. Wanted – stopped, wanted – sat down again and drove off! It doesn’t work that way!

Russia is a continent, and we cannot blame us here for anything. And then we alone are excommunicated from Europe, so, Europe is uniting and conducting some kind of talk there. The Russian-European part is larger than the whole of Europe taken together at times! Why are they excommunicating us ?! Europe is our home, by the way, and not of those who are trying to create all this and forcing it. It is useless.

Has the ruble collapsed with me? What are you guys? When did you manage it all? They have done it, it means that there is something here, now I have also collapsed the ruble! (about the 1998 crisis)

We must end with tax surrealism.

Today the world financial system understands what is happening in Russia and does not really want it to be here … well, I don’t want to use this word, which I usually use.

Nothing today, nothing tomorrow, and then they woke up – and yesterday, it turns out, nothing.

Now historians are trying to present that in fifteen hundred and some year there was something there. There was nothing! All this is machinations!

No sooner said than done. I do not understand – ask again. I didn’t understand the first time – ask again. But do it. If you can’t – report why you are not doing it, for what reason. Nothing else is required of you.

Hear what is expected of us? S-300. We know what it is. God forbid it. Today is the S-300. And tomorrow, let’s do something else. And the day after tomorrow is the third.This is what it is. (about the Balkan conflict)

The country does not know what the government is eating.

What those whom you name are declaring there, I do not even want to call them that word – they should not be there.

I have no questions about the Russian language.

Our trouble is not to unite, but who is in charge.

We still have people who live very badly. We see it, drive it, hear it, read it.

– Do you have time to notice beautiful women?

– I have time.But just notice. Nothing more. What I regret bitterly.

Clever found! Declare war on him! Hands! His! Too! And this! Immediately like this! And what does he know at all! And who is he! Still somewhere and climbs, I’m sorry. (about Zyuganov’s proposal to declare war on NATO)

Teachers and doctors want to eat almost every day!

We wanted the best, but it turned out as always (about the first Chechen war)

I would like to deeply thank you for the expressed confidence in appointing me ambassador to our neighbor’s brother, the Republic of Ukraine.

Prices need to be raised, you see how: as soon as Chubais opens his mouth, he will be immediately pissed off, if you please.

What wrong have we done before God, Allah and others?

It is impossible to sew anything to Chernomyrdin.

What to say about Chernomyrdin and me?

These elections turned out to be an ordeal for us. This should never happen again.

This is not the organ that is ready for love.

This ghost … wanders somewhere out there, in Europe, but for some reason it stops here.We’ve had enough strangers.

I would not want me to blame someone or not recognize there today. This is already a matter for the prime minister.

I always wondered why Kosygin walked gloomy, never smiled, although everyone around was smiling and kissing passionately. And then, when I myself became prime minister, I realized how hard it is …

I am ready and will unite. And with everyone. You can’t, excuse the expression, all the time in a splash.

I am ready to invite everyone to the cabinet – both white and red and colorful.If only they had ideas. But they only show their tongue and something else.

I cannot take offense at Zyuganov. And I’m not offended. We do not take offense at such people.

I’m not a diplomat. And I’m not going to be a diplomat. And the fact that we have reached an agreement is absolutely non-diplomatic. Absolutely. (about the Balkan conflict)

I do not think that the governor should work in such a way as to harm.

I am not a person who lives on satisfaction.

I won’t say anything, otherwise I’ll say something again.

I just want to say to make it easier for everyone and understand that we are not inventing anything new. We formulate our country.

I will be able to work with Seleznev, but with individual members … I do not see them point-blank for their actions.

I also carry a heavy load. And my voice sat down too. And I didn’t even drink yesterday.

Related Posts

Leave a Reply